Abstract | Covalent attachment (conjugation) of one or more ubiquitin molecules to protein substrates governs numerous eukaryotic cellular processes, including apoptosis, cell division and immune responses. Ubiquitylation was originally associated with protein degradation, but it is now clear that ubiquitylation also mediates processes such as protein-protein interactions and cell signalling depending on the type of ubiquitin conjugation. Ubiquitin ligases (E3s) catalyse the final step of ubiquitin conjugation by transferring ubiquitin from ubiquitin-conjugating enzymes (E2s) to substrates. In humans, more than 600 E3s contribute to determining the fates of thousands of substrates; hence, E3s need to be tightly regulated to ensure accurate substrate ubiquitylation. Recent findings illustrate how E3s function on a structural level and how they coordinate with E2s and substrates to meticulously conjugate ubiquitin. Insights regarding the mechanisms of E3 regulation, including structural aspects of their autoinhibition and activation are also emerging.
Ubiquitin ligases (E3s) are a large family of enzymes that catalyse the covalent attachment of a small protein modifier, ubiquitin, to a plethora of substrates in eukaryotic cells. Ubiquitylation (also known as ubiquitination) plays a fundamental part in nearly all aspects of eukaryotic cellular processes. By marking substrates with ubiquitin, E3s bestow these substrates with new platforms for proteinprotein interactions that alter their activity, localization and/or further interactions, thereby eliciting distinct biological signals.
Ubiquitylation is achieved by the sequential actions of a ubiquitin-activating enzyme (E1), a ubiquitinconjugating enzyme (E2) and an E3 (REFS 1-3) (FIG. 1a) . An E1 uses a magnesium ion and ATP to form a covalent thioester bond between its catalytic cysteine and the di-glycine motif at the carboxyl terminus of ubiquitin. The E1 then transfers ubiquitin, again through its di-glycine motif, to the catalytic cysteine of an E2 to form an E2~ubiquitin thioester complex (~is used to indicate a thioester bond throughout the manuscript). An E3 then binds E2~ubiquitin and the substrate to facilitate the formation of an isopeptide bond between the C terminal carboxyl of ubiquitin and the ε-amino group of a lysine side chain or free amino terminal amino group of the substrate. Successive rounds of E3-catalysed reactions can produce substrates with polyubiquitin chains linked via one of the seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) or N-terminal methionine (Met1) of ubiquitin 4 (FIG. 1b) . Recognition of different ubiquitylation patterns by various effectors harbouring a ubiquitin-binding domain elicits distinct downstream signals. For example, Lys48-linked polyubiquitin targets a substrate to the 26S proteasome for degradation 5, 6 , whereas Lys63-linked polyubiquitin directs a substrate to the endocytic pathway 7 and regulates kinase activation in the NF-κB pathway 8 . By contrast, monoubiquitylation is involved in DNA repair 9, 10 and chromatin remodelling 11 . The human genome encodes two E1s, approximately 38 E2s and more than 600 E3s [12] [13] [14] . Within this enzymatic cascade, E3s play a pivotal part in selecting substrates and, together with E2~ubiquitin, they coordinate the conjugation of specific ubiquitin linkages onto substrates. In this Review, we discuss the three classes of E3s identified to date: RING (really interesting new gene), HECT (homologous to E6AP C-terminus) and RBR (RINGbetween-RING). We focus on recent structural insights into the mechanisms by which E3s recruit E2~ubiquitin, how they prime and position ubiquitin and the substrate lysine for transfer, and how they extend ubiquitin chains to achieve polyubiquitylation. Moreover, we discuss structural details of emerging themes in E3 regulation, including autoinhibition.
Overview of E3s and their features
All E3s harbour an E2~ubiquitin-binding domain and are classified on the basis of the structure of this domain and their ubiquitin transfer mechanism. RING E3s catalyse the direct transfer of ubiquitin from E2~ubiquitin to the substrate. By contrast, HECT and RBR E3s contain a catalytic cysteine that first receives ubiquitin from E2~ubiquitin to form an E3~ubiquitin thioester intermediate, followed by the transfer of this ubiquitin to the substrate (FIG. 2) .
Isopeptide bond
An amide bond formed between the amino group of a lysine side chain on a protein (substrate) and the carboxyl terminus of another protein (ubiquitin).
ε-amino group
Refers to the NH 3 + group in a lysine side chain. This group has a high acid dissociation constant (pK a ), and often the active site environment (or environments) of ubiquitinactivating and ubiquitinconjugating enzymes or substrates can assist in lowering the pK a of this NH 3 + group to increase its reactivity.
26S proteasome
A large protein complex that degrades proteins modified with ubiquitin chains. The 26S proteasome contains a 20S core particle that accommodates the protease catalytic subunits and two 19S regulatory subunits that recognize ubiquitylated substrates and facilitate substrate unfolding before entry into the 20S core particle.
NF-κB pathway
A signalling pathway that activates the transcription factor nuclear factor-κB (NF-κB) in response to stimuli such as pro-inflammatory cytokines, bacterial and viral infections, and antigen receptor binding. Activated NF-κB leads to the expression of genes that are regulators of apoptosis, cell survival, proliferation and immunity.
Substrate targeting by E3s. The mechanism by which E3s target substrates varies. Some E3s contain one or several protein-protein interaction domains to which a substrate can bind directly or indirectly (via an interacting partner). E3s can also interact with a substrate by both direct and indirect means. For example, the E3 CBL downregulates epidermal growth factor receptor (EGFR) signalling by ubiquitylating and targeting the EGFR for lysosomal degradation. CBL harbours a substratebinding domain that recognizes phosphorylated EGFR as well as a domain that binds the EGFR-interacting protein GRB2, which recruits CBL to EGFR 15, 16 . In addition, some E3s contain domains that bind non-protein molecules to mediate substrate binding and ubiquitylation. For example, in the endoplasmic reticulum-associated degradation system, the E3 cullin-RING ligase (CRL) forms a complex with the sugar-binding receptor FBS1 (CRL FBS1 ) to recruit and ubiquitylate N-linked glycoproteins 17 . Other E3s lack specificity in their substrate selection but instead contain a domain or a binding motif that recruits them to defined sites within the cell where they then ubiquitylate any accessible target. For example, during the repair of DNA lesions induced by ultraviolet light, the E3 CRL-DDB complex (CRL DDB ) binds directly to pyrimidine dimer photolesions and ubiquitylates DNAbound XPC and DDB2 to initiate the nucleotide excision repair pathway [18] [19] [20] . For many E3s, the substrate targeting mechanism is unknown. In the following paragraphs we describe each of the three classes of E3s in more detail.
Characteristics of RING E3s. Bioinformatic analyses predict that there are approximately 600 RING E3s in humans, making RING E3s the largest of the three E3 classes 14 (Supplementary information S1 (table) ). RING E3s are characterized by the presence of a RING domain (FIG. 2a-e) , which is the minimal component required to recruit E2~ubiquitin and to stimulate ubiquitin transfer 21 . Structurally, RING domains are characterized by the presence of two zinc ions coordinated by cysteine residues and histidine residues arranged in Figure 1 | The ubiquitin conjugation system. a | A ubiquitin-activating enzyme (E1) catalyses two rounds of adenylation of ubiquitin in the presence of Mg 2+ and ATP to bind two molecules of ubiquitin: one ubiquitin forms a thioester bond with the catalytic cysteine (shown in beige) of E1 and the other ubiquitin (shown in pink) is bound non-covalently via its AMP-modified carboxyl terminus to the adenylation domain of E1. E1 then binds a ubiquitin-conjugating enzyme (E2) and transfers ubiquitin from its catalytic cysteine to the catalytic cysteine of E2 to form E2~ubiquitin (~ indicates a thioester bond). E2~ubiquitin dissociates from E1 and E1 re-enters its catalytic cycle. A ubiquitin ligase (E3) recruits E2~ubiquitin and a substrate to catalyse ubiquitin transfer to a lysine on the substrate. Upon transfer, E2 disengages from E3 and E3 binds another E2~ubiquitin to catalyse the next round of substrate ubiquitylation. b | Substrate ubiquitylation outcomes. Ubiquitylated substrates interact with binding partners that harbour ubiquitin-binding domains, thus altering proteinprotein interactions and cellular functions of substrates. A single molecule of ubiquitin can be attached to a substrate at one (monoubiquitylation) or multiple (multi-monoubiquitylation) lysine sites. Additionally, the seven surface lysine residues and amino-terminal methionine (Met1) of ubiquitin can serve as acceptor sites, leading to the formation of polyubiquitin chains. These chains can be homogeneous, such as Lys48-linked and Lys63-linked polyubiquitin, whereby only one site on ubiquitin is modified, or they can be branched, whereby two molecules of ubiquitin are attached to different acceptor sites on a single ubiquitin molecule. Different ubiquitin linkages vary in structure and therefore recruit discrete interacting partners to produce unique downstream signals 152, 160 .
Pyrimidine dimer photolesions
Ultraviolet radiation-induced dimer formation between two consecutive pyrimidine bases on one strand of DNA. This process breaks the normal base pairing in double-stranded DNA.
a cross-braced configuration (FIG. 2a-d 
PY motifs
Short proline-rich motifs containing a proline-prolinex-tyrosine (x is any amino acid) sequence that is recognized by a WW domain.
Allosteric changes
Refer to changes induced in one part of a molecule, usually an active site of an enzyme, by a distal binding event. Small-angle X-ray scattering (SAXS) . A technique whereby the elastic scattering of X-rays by a protein in solution is used to provide information about the protein's shape and size.
Nuclear magnetic resonance (NMR)
substrate receptor defines substrate specificity (FIG. 2d) .
There are approximately 300 different substrate receptors in humans, making CRLs versatile at ubiquitylating numerous substrates. APC/C is a 1.2 MDa complex consisting of a 14-subunit core complex, including the RING E3 APC11, the cullin-like subunit APC2 and a co-activator protein (CDC20 or CDH1) that recruits the substrate 36 . Finally, U-box proteins are also classified as RING E3s: they use the same ubiquitin transfer mechanism and resemble the RING domain in structure but lack zinc ions 37 . There are eight U-box E3s in humans 14 and, similar to the RING E3s, some function as monomers, such as UBE4B 38 , whereas others, such as PRP19 (REF. 39 ) and CHIP 40 , require dimerization for activity (Supplementary information S1 (table)).
Characteristics of HECT E3s. There are 28 HECT E3s in humans 41 . In general, they comprise an N-terminal substrate-binding domain and a C-terminal HECT domain of approximately 350 amino acids containing the catalytic components for ubiquitin conjugation and transfer. HECT E3s are subdivided into three groups based on their N-terminal protein-protein interaction domains: first, the NEDD4 family, which is characterized by the presence of WW domains that bind PY motifs in substrates; second, the HERC family, which contains regulator of chromosome condensation 1-like domains that are not well characterized; and third, HECTs with other protein-protein interaction domains 41 (Supplementary information S1 (table)). HECT domains themselves contain two lobes connected by a flexible hinge loop (FIG. 2f) . The N-terminal lobe (N-lobe) binds E2~ubiquitin and the C-terminal lobe (C-lobe) contains the catalytic cysteine 42 (FIG. 2g) . The flexible hinge enables the lobes to rotate, which supports ubiquitin transfer 43 .
Characteristics of RBR E3s. The 14 RBR E3s identified in humans all possess a RING1-IBR-RING2 motif (FIG. 2h; see Supplementary information S1 (table)) as well as other domains 14, 44, 45 . Of the RBR E3s, PARKIN, HHARI and HOIP are characterized best. Early studies showed that the RING1-IBR-RING2 motif was essential for E2 binding and ubiquitin ligase activity, but the mechanism of ubiquitylation by RBR E3s remained elusive and was thought to resemble that of RING E3s [46] [47] [48] [49] . However, in 2011, a conserved catalytic cysteine in the RING2 domain of HHARI and PARKIN was identified and found to form a thioester intermediate with the C terminus of ubiquitin in a HECT E3-like manner 50 . This finding redefined the RBR E3 mechanism as a hybrid of RING and HECT E3s, whereby the RING1 domain recruits E2~ubiquitin and transfers ubiquitin onto the catalytic cysteine of the RING2 domain before its conjugation to a substrate (FIG. 2i) .
Structural basis of RING E3 activity E2s contain a highly conserved core domain of approximately 150 residues, including a catalytic cysteine that forms a covalent thioester bond with the C terminus of ubiquitin to generate E2~ubiquitin 13 . In the absence of an E3, ubiquitin transfer from E2~ubiquitin to an amine of a substrate can occur but the process is inefficient. The addition of a RING E3 massively stimulates this process 24, [50] [51] [52] [53] , but the mechanism underlying this stimulation was not well understood until recently.
In 2000, the first crystal structure of a RING E3-E2 complex was resolved (CBL-UBE2L3 complex), showing that the active site of E2 is distal from the RING domain, precluding direct participation of the RING domain in catalysis 22 . Although CBL is not reactive with UBE2L3, similar E3-E2 conformations have been found in subsequently determined structures of reactive RING E3-E2 pairs. Subsequent studies suggested that RING E3 binding might induce allosteric changes in the active site of E2s 51, 54 , but details remained elusive. In 2012, the crystal structures of RNF4 (REF. 55 ) and BIRC7 (REF. 56 ) bound to E2~ubiquitin (~ denotes a covalent interaction used for crystallization purposes to mimic E2~ubiquitin) and nuclear magnetic resonance (NMR) analyses of E4B in complex with the E2 UBE2D3~ubiquitin 57 finally revealed the details of the catalytic mechanism of RING E3-mediated ubiquitin transfer (FIG. 3) . These details are discussed below.
Priming ubiquitin for transfer. NMR and small-angle X-ray scattering (SAXS) analyses showed that in the absence of a RING E3, the structure of UBE2D3~ubiquitin is highly dynamic and prefers to adopt open conformations in which there are little or no interactions between the E2 and ubiquitin. Similarly, it has been shown that the E2 UBE2N~ubiquitin conjugate is dynamic, although it more frequently adopts closed conformations compared with UBE2D3 (REF. 58 ). For the UBE2D family of E2s, it has been revealed that the addition of a RING E3 shifts the equilibrium towards closed conformations in which ubiquitin is proximal to the RING domain and more reactive towards transfer 56, 57, 59, 60 (FIG. 3a) . When ubiquitin is optimally positioned or primed for transfer, the RING domain binds both the E2 and the Ile36 surface of ubiquitin, and the Ile44 surface of ubiquitin contacts α2 of the E2 (FIG. 3b) . This conformation ensures that the C-terminal tail of ubiquitin (residues 71-76) is braced in a position favourable for catalysis in which the E2~ubiquitin thioester is optimally oriented for nucleophilic attack by the incoming substrate lysine.
The acquisition of a primed ubiquitin conformation in the presence of a RING E3 appears to be conserved across different E2s and RING E3s and has been corrobor ated by various crystal structures 24, 55, 56, [61] [62] [63] [64] [65] and biochemical studies 53, 66 . Collectively, these studies show that several E2~ubiquitin conjugates are not reactive for transfer of ubiquitin onto a lysine because they adopt various inactive conformations; interactions with RING E3s favour the acquisition of a closed E2~ubiquitin conformation in which ubiquitin is primed for transfer.
Key interactions in the primed conformation. The side chain of an arginine from the RING E3 forms hydrogen bonds with both the E2 and ubiquitin, thereby functioning as a 'linchpin' (REF. 57 ) within the RING E3-UBE2D~ubiquitin interface to stabilize the primed ubiquitin conformation (FIG. 3c) . Direct interactions between this linchpin arginine and the carbonyl of Arg72 of ubiquitin contribute to constraining the C-terminal tail of ubiquitin in an activated conformation along the active site cleft of the E2. Most E2s contain a His-ProAsn motif within their active sites that is critical for catalysis. The asparagine from this motif stabilizes the loop comprising residues 114-117 from the E2 UBE2D2 (REFS 55, 67) (FIG. 3d) . This loop helps stabilize the tail of ubiquitin and, as observed in the SUMO-conjugating E2 (REF 68) , contains an aspartate that reportedly reduces the acid dissociation constant (pK a ) of the incoming substrate lysine, thereby making the lysine more reactive towards the E2~ubiquitin thioester and facilitating catalysis 55 . Although the RING domain alone primes E2~ubiquitin 57 , the presence of various additional ubiquitin-binding components in the sequence of some RING E3s serves to further stabilize E2~ubiquitin in the primed conformation and enhances the enzymatic activity of the E3-E2~ubiquitin complex 55 Thr9 side chain of ubiquitin 61 , and in RNF38, loops adjacent to the RING domain of RNF38 contact the Thr9-containing surface of ubiquitin 24 . In another example, ubiquitin transfer by the monomeric RING E3 ARK2C requires binding of a second molecule of ubiquitin to the RING domain opposite the E2-binding surface; modelling and biochemical data suggest that this ubiquitin directly contacts and stabilizes the E2-conjugated ubiquitin for transfer 69 . For the dimeric RING E3s RNF4 and BIRC7, the RING domain of one subunit and the C-terminal tail of the second RING subunit interact with the Gly35-containing surface of ubiquitin 55, 56 . A conserved aromatic residue in the C-terminal tail from both of these dimers is critical for this interaction. By contrast, the RING E3 TRIM25 has a different dimer interface and the tail lacks this aromatic residue. In the TRIM25~UBE2D1~ubiquitin complex structure, the N-terminal helix from one subunit and C-terminal helix from the second subunit make hydrophilic interactions with the Gly35-containing surface of ubiquitin 65 . For many RING E3s, these additional components are distinct features that require additional structural and biochemical studies to fully characterize their roles in RING E3-mediated ubiquitylation.
Additional E2-E3 interactions. Several RING E3s
harbour an additional domain that binds to the 'backside' surface of the E2 opposite the active site (FIG. 3f) . Examples of these backside interactions include the G2BR domain of gp78 with the E2 UBE2G2 (REF. 70 ), the U7BR domain of Cue1p with UBC7 (REF. 71 ), the R6BD domain of RAD18 with RAD6 (REF. 72 ), and the U5BR domain of AO7 with UBE2D2 (REF. 73 ). These various E3 domains that facilitate backside binding of E2s all enhance RING E3-E2 affinity but affect activity dispar ately. G2BR stimulates ubiquitylation by inducing conformational changes at the RING-UBE2G2 interface that enhance UBE2G2~ubiquitin binding 70 . Moreover, RING domain binding modulates G2BR-UBE2G2 affinity to facilitate the release of UBE2G2, thereby promoting processive ubiquitylation 74 . U7BR binding not only enhances RING E3-E2 affinity but also increases the accessibility of the active site of UBC7 to E1 and Lys48 of ubiquitin to facili tate recharging of the E2 with ubiquitin and promote further rounds of substrate ubiquitylation 71 . In addition to backside binding by RING E3s, some E2s, such as RAD6 and the UBE2D family, also establish non-covalent backside interactions with ubiqui tin (FIG. 3f) and this interaction promotes processive polyubiquitin chain formation 72, [75] [76] [77] . For UBE2D2, this non-covalent ubiquitin binding induces allosteric changes in the E2 that increase the affinity of RING E3s for E2~ubiquitin and the catalytic efficiency of ubiquitylation, leading to enhanced initial ubiquitin transfer and subsequent polyubiquitin chain formation 24 . As discussed above, U5BR enhances the affinity of AO7 for UBE2D2. This enhanced affinity, however, blocks non-covalent ubiquitin binding, leading to decreased ubiquitylation activity 73 . Similarly, R6BD binding to RAD6 competes with non-covalent ubiquitin binding, thereby limiting RAD18-mediated ubiquitylation 72 .
Transfer of ubiquitin onto substrate. The main role of RING E3s in ubiquitin transfer is to prime the ubiquitin in the E2~ubiquitin complex and to juxtapose a substrate lysine and the E2~ubiquitin thioester. The mechanism by which different RING E3s accomplish this process varies and details are only beginning to emerge. In each case, the capacity for a substrate lysine to be ubiquitylated is governed by both the target protein structure as well as precisely regulated structural constraints of the E3-E2~ubiquitin complex. This process is further discussed below, when we consider how substrate ubiquitylation outcomes are defined.
Structural basis of HECT E3 activity HECT E3s are characterized by the presence of an N-lobe, which is connected by a hinge to a C-lobe containing the catalytic cysteine (FIG. 2f) . The N-lobe establishes interactions with E2, which involve the L1 and L2 loops and N-terminal α1 of E2 binding to an 80-residue subdomain in the HECT E3 N-lobe 42, 78, 79 . Following the binding of E2~ubiquitin, ubiquitin is transferred from the E2 to the catalytic cysteine on the C-lobe of the HECT domain in a transthiolation reaction. The HECT~ubiquitin is then subsequently juxtaposed with a substrate lysine to which ubiquitin is transferred.
Mechanism of transthiolation.
In structures of the HECT E3s E6AP, WWP1 and SMURF2, the position of the C-lobe relative to the N-lobe varies, demonstrating that the hinge between the two lobes is flexible 42, 43, 80 ( FIG. 4a-c) . Early structures and models of HECT E3-E2 complexes revealed a large distance between the E2 and HECT E3 catalytic cysteine residues, suggesting that conformational changes are required for the E2-E3 trans thiolation reaction (FIG. 4c) . Subsequently, the crystal structure of NEDD4L bound to UBE2D2~ubiquitin indicated that a rotation about the hinge was involved in positioning the catalytic cysteine of the C lobe adjacent to the UBE2D2~ubiquitin linkage, thereby allowing transthiolation 78 (FIG. 4d) . In the current model of NEDD4L transthiolation, the N-lobe initially recruits E2~ubiquitin, and upon rotation about the hinge, the C-lobe binds ubiquitin and juxtaposes both catalytic cysteine residues to promote the formation of the HECT E3~ubiquitin intermediate. This hinge rotation transthio lation mechanism is likely to be shared among HECT E3s. For the NEDD4 family of HECT E3s, hydrophobic interactions between ubiquitin and conserved residues on the C-lobe facilitate transthiolation. However, these C-lobe residues are not conserved in other HECT E3s; hence, further studies are required to elucidate how these other HECT E3s engage ubiquitin for transthiolation.
Priming ubiquitin for transfer. The step immediately following the transthiolation reaction was captured in a crystal structure of a NEDD4~ubiquitin complex 81 (FIG. 4e) . The interactions between ubiquitin and the C-lobe are identical to those observed in the structure of NEDD4L-UBE2D2~ubiquitin complex before transfer (FIG. 4d) Flexible hinge loops, which enable C-lobe rotation and ubiquitin transfer, are indicated. In part c, the distance between ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3) catalytic cysteine residues is indicated. d | Structure of a NEDD4L HECT-UBE2D2~ubiquitin complex (PDB: 3JVZ; ~ denotes a covalent interaction used for crystallization purposes). The UBE2D2~ubiquitin linkage and the catalytic cysteine of the C-lobe are juxtaposed, allowing transthiolation of ubiquitin from the E2 to the catalytic cysteine of the E3. e | Structure of the NEDD4 HECT domain following transthiolation (PDB: 4BBN). In this case, NEDD4 is bound to two ubiquitin molecules, one of which is a covalently attached to the catalytic cysteine in the C-lobe (coloured wheat) and a second one is noncovalently bound to the N-lobe, which enhances the processivity of complexes, in the NEDD4~ubiquitin complex, the C-terminal tail of ubiquitin is positioned in an extended conformation (by a hydrogen bond network involving backbone carbonyl oxygen moieties and amides from the HECT domain C-lobe). Together, based on the available E3-E2~ubiquitin structural data, constraining the position of the C terminus of ubiquitin appears to be a common thioester-activating mechanism for RING and HECT E3s.
Transfer of ubiquitin to substrate. Following transthiolation, the E3~ubiquitin thioester in HECT is juxtaposed with a substrate lysine. This process was recently captured in the crystal structure of Rsp5~ubiquitin-Sna3 complex in which a three-way chemical crosslinker was used to link the catalytic cysteine of Rsp5, the C terminus of ubiquitin and a lysine side chain of the Sna3 substrate peptide 82 (FIG. 4f) . This structure revealed that the C-lobe undergoes a 130° rotation about the flex ible linker relative to its conformation in the NEDD4L-UBE2D2~ubiquitin and NEDD4~ubiquitin complexes (FIG. 4e-g ). Almost half of the N-lobe contacts the C-lobe to stabilize this conformation. Crucially, Phe806 from the C-lobe of Rsp5, also known as the '-4 phenylalanine' , sits in an N-lobe pocket containing Phe505 and Leu506. This -4 phenylalanine is conserved in all types of HECT E3s and is required for substrate ubiquitylation and polyubiquitin chain formation but not HECT~ubiquitin formation 83, 84 . Interestingly, mutations of this Phe to Leu (Rsp5 F806L) can be rescued by a complementary substitution of Leu506 to Trp (L506W) or to Phe (L506F), suggesting that Phe806 anchors the two HECT domain lobes in an orientation suitable for substrate ubiquitylation 82 . It is noteworthy that the amino acid composition of this N-lobe pocket is conserved in the NEDD4 E3s, suggesting that this subfamily of HECT E3s uses a similar mechanism to orient the N-and C-lobes for ubiquitin transfer to substrates. In other HECT E3 subfamilies, the amino acid composition of this pocket diverges, and further investigations are needed to elucidate how these E3s anchor their N-and C-lobes for ubiquitin transfer to a substrate. Furthermore the extreme C terminus of HECT E3s has been shown to be important for ligation 81, 83 , but this region is disordered in all HECT E3 structures. Future studies are required to investigate the role of the C terminus in ligation.
The Rsp5~ubiquitin-Sna3 structure does not capture a substrate lysine poised for ligation, but modelling and mutational analyses suggest that residues surrounding the catalytic cysteine of Rsp5 contribute to Sna3 ubiquitylation 82 . The Rsp5~ubiquitin thioester sits adjacent to an N-lobe loop (residues 490-495) harbouring Asp495 (FIG. 4f) , an essential residue for ligation 82 . This loop is disordered in the Rsp5~ubiquitin-Sna3 structure. Modelling based on other HECT E3 structures, in which the loop is ordered and contains this structurally conserved aspartate, suggests that this loop may function in stabilizing the C terminus of ubiquitin. Additionally, in the model, Asp495 juxtaposes with the E3~ubiquitin thioester, where it can potentially interact with a substrate lysine and orient it into the active site or contribute to substrate lysine deprotonation 82 . Future studies are required to determine how the aspartate-containing N-lobe loop and active site residues participate in substrate ubiquitylation and chain elongation in HECT E3s.
The NEDD4-family HECT E3s harbour a noncovalent ubiquitin-binding site on the N-lobe 80, 81, [85] [86] [87] (FIG. 4e) . Disruption of this interaction impairs polyubiquitin chain elongation but not E2-E3 transthiolation or the conjugation of the first ubiquitin to a substrate 86, 87 . This non-covalent ubiquitin is distal from the E3~ubiquitin thioester in all available structures, suggesting it does not serve as a substrate ubiquitin, or acceptor ubiquitin, in ubiquitin chain elongation. Biochemical data suggest that this site might bind ubiquitin-modified substrate, thereby promoting processive polyubiquitin chain formation 87 . However, the exact function of this non-covalent ubiquitin binding remains to be determined.
Structural basis of RBR E3 activity
Structures of PARKIN, HHARI and HOIP show that structures of RING1, IBR and RING2 domains from different RBR E3s are conserved [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] . RING1 adopts a cross-braced zinc ion-coordination configuration found in typical RING domains, whereas IBR and RING2 each have two zinc ions coordinated in a linear fashion. RING1 recruits E2~ubiquitin and transfers ubiquitin to the catalytic cysteine on RING2 to form a RING2~ubiquitin intermediate; ubiquitin is subsequently transferred to substrate (FIG. 2h,i) . Various structures of PARKIN, HHARI and HOIP show distinct RING1-IBR-RING2 arrangements (FIG. 5) . In the structure of the RBR region (that is the region encompassing the RING1-IBR-RING2 domains of the protein) from HOIP bound to E2~ubiquitin, the RBR adopts a conformation that is competent for ubiquitin transfer 92 . In the full-length structures of PARKIN and HHARI, both adopt autoinhibited conformations (discussed below) that are not competent for ubiquitin transfer whereby the arrangement of the RBR motif is determined by other domains unique to each of these E3s [93] [94] [95] [96] [97] : the RING0 domain in PARKIN and a C-terminal Ariadne domain in HHARI. In these autoinhibited states, RING0 is sandwiched between RING1 and RING2 with IBR placed adjacent to RING1, whereas the Ariadne domain is stacked between IBR and RING2, positioning RING1 and a ubiquitin-associated (UBA) domain distal to RING2 (FIG. 5a,b) .
Formation of RING2~ubiquitin.
Given the structural similarity between the RING1 and canonical RING domains, modelling of the RING1 domain from PARKIN and HHARI onto RING E3-E2~ubiquitin complexes revealed that these RING1 domains harbour similar hydrophobic cores to canonical RING domains that interact with hydrophobic residues in the L1 and L2 loops of E2s (FIG. 5c,d ). These hydrophobic interactions were observed in the structure of the RBR module from HOIP bound to UBE2D2~ubiquitin 92 . However, RING1 domains lack the linchpin arginine conserved in RING E3s that promotes the closed, primed E2~ubiquitin conformation required for ubiquitin transfer to a lysine (see above). In contrast to RING E3s, RBR E3s function with UBE2L3, an E2 that preferentially transfers ubiquitin to cysteine rather than lysine 50 . In addition, it has been shown that HHARI without its RING2 or with catalytically dead RING2 cannot promote transfer of UBE2L3~ubiquitin, indicating that RING1 cannot promote ubiquitin transfer 50, 93 . Taken together, these studies suggest that the RING1 domain does not activ ate E2~ubiquitin like a canonical RING E3. Instead, these data indicate that the RBR E3s resemble HECT E3s in function: depending on the class of E3 (HECT versus RBR), either the N-lobe or RING1 recruits E2~ubiquitin and then the juxtaposition of E2~ubiquitin with the C-lobe or RING2 promotes the formation of E3~ubiquitin.
The recent HOIP-UBE2D2~ubiquitin complex structure reveals how these catalytic cysteine residues are juxtaposed 92 . Multiple interactions with RING1, RING2, IBR and regions between these components stabilize UBE2D2~ubiquitin in an open conformation 92 (FIG. 5e) .
The RING1-IBR module adopts an elongated conformation in which RING1 and IBR are connected by two extension helices, h E1 and h E2 . RING1 binds UBE2D2 and h E2 -IBR binds the surface of ubiquitin containing Lys11 and Glu34. The Ile44 surface of ubiquitin also contacts a helix between IBR and RING2, thereby enabling RING2 to bind UBE2D2 and to stabilize the C-terminal tail of ubiquitin in an extended conformation. In this conformation, the UBE2D2 and RING2 catalytic cysteine residues are juxtaposed and the ubiquitin is optimally positioned for transfer. HOIP harbours an additional ubiquitinbinding site on the RING1-IBR region, opposite the UBE2D2~ubiquitin-binding site. This ubiquitin (hereby referred to as ubiquitin Allo ) functions as an allosteric activ ator by enhancing UBE2D2~ubiquitin binding and RING2~ubiquitin formation. Similar to HOIP, PARKIN and HHARI both have similar RING1-IBR-RING2 modules and two helices between RING1 and the IBR region (FIG. 5a,b,e) , suggesting that they share a similar mechanism of E2~ubiquitin binding. How PARKIN and HHARI undergo conformational changes to juxtapose E2~ubiquitin with the catalytic cysteine of RING2 and how other domains influence this transition remains to be determined.
Transfer of ubiquitin to the substrate. Our current understanding of how RBR E3s recognize their substrates is limited to HOIP-mediated linear ubiquitin chain formation (that is, the formation of a Met1-linked polyubiquitin chain). This process is facilitated by the presence of a linear ubiquitin chain-determining domain in HOIP that binds and orients the acceptor ubiquitin 98, 99 . The HOIP-ubiquitin complex crystal structure captures both donor and acceptor ubiquitin in conformations poised for linear ubiquitin chain synthesis 88 . Both RING2 and the linear ubiquitin chain-determining domain bind to the acceptor ubiquitin, whereas the C terminus of the donor ubiquitin is positioned next to the active site cysteine of RING2, thereby mimicking a HOIP~ubiquitin intermediate (FIG. 5f) . The C-terminal tail of the donor ubiquitin lies along a hydrophobic groove surrounding the catalytic cysteine in the core of the RING2 domain; interactions with this groove and a β-hairpin from the RING2 domain stabilize the tail in an extended conformation (FIG. 5f) . The RING2 domains from PARKIN and HHARI also contain hydrophobic grooves proximal to the catalytic cysteine, suggesting that these E3s may use an E3~ubiquitin-binding mode similar to HOIP when mediating ubiquitin transfer to a substrate. However, PARKIN and HHARI lack the β-hairpin present in HOIP and have different domains outside the RBR motif implicated in substrate binding; hence, further studies are required to elucidate how PARKIN and HHARI juxtapose RING2~ubiquitin and a substrate.
Based on structural analyses, it appears that the mode of ubiquitin binding in HOIP RING2-ubiquitin and HOIP-UBE2D2~ubiquitin complexes is identical, suggesting that the ubiquitin-binding mode is maintained throughout E2-E3 ubiquitin transfer and substrate ubiquitylation 92 . In addition, when overlaid, the acceptor ubiquitin-RING2 interaction overlaps with the UBE2D2-RING2 interface in the HOIPUBE2D2~ubiquitin complex, suggesting that acceptor ubiquitin and E2~ubiquitin binding are mutually exclusive. Thus, it seems that for successive rounds of substrate ubiquitylation, acceptor ubiquitin of the 
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Multivesicular body
A type of late endosome that contains membrane-bound vesicles within its lumen. Fusion with lysosomes leads to degradation of its contents, whereas fusion with the plasma membrane releases its contents into the extracellular space.
Crystallographic symmetry
Crystals are formed from repeating subunits in which the minimal subunit is referred to as the asymmetric unit. Crystallographic symmetry refers to how these asymmetric units pack to form a crystal.
Polycomb-group proteins
A family of proteins that have important roles in cellular differentiation and development by remodelling chromatin to repress transcription. They form part of the multiprotein complexes called Polycomb repressive complexes.
Nucleosome core particle (NCP). A basic repeating unit of DNA packaging found in eukaryotes. A single NCP contains 147 base pairs of DNA wrapped around a histone octamer consisting of two histone H2A-H2B dimers and a histone H3-H4 tetramer.
substrate must be released from RING2 after transfer to allow additional rounds of E2~ubiquitin recruitment and RING2~ubiquitin complex re-formation (FIG. 5g) . How such arrangements contribute to ubiquitin chain elongation is currently unclear. (FIG. 1b) . Polyubiquitylation involves two events: chain initiation, in which ubiquitin is transferred to a lysine on the substrate, and chain elongation, in which ubiquitin is transferred to a lysine on a ubiqui tin moiety from ubiquitylated substrate. For some RING E3s, a single E2 is reportedly responsible for both events 75 whereas in other RING E3s one E2 participates in the addition of the first ubiquitin to the substrate and a second E2 is involved in chain elongation [100] [101] [102] . To mediate this array of ubiquitylation outcomes, diverse mechanisms are required. For monoubiquitylation, E3s require a method to prioritize or isolate a single lysine on a substrate. By contrast, for multimonoubiquitylation and chain elongation, E3s must be flexible to bridge the varying distances between the E3~ubiquitin or E2~ubiquitin thioester and the target lysine. Flexibility is also required in E3s that interact with multiple substrates via discrete domains.
Defining the outcome of ubiquitylation
Currently, no consensus ubiquitylation motif has been determined that would indicate the outcome of ubiquitylation for a particular substrate. For RING E3s, it is widely accepted that the E2 specifies the ubiquitin chain type or lysine site that is modified; however, it is the RING E3 that regulates the accessibility of substrate lysine residues to the E2~ubiquitin thioester. The emerging theme from recent structural studies of E2-RING E3-substrate, E2~ubiquitin-RING E3-substrate and HECT E3~ubiquitin-substrate complexes illustrates that spatial arrangements and surface complementarity prioritize lysine site (or sites) for ubiquitylation 64, 82, [103] [104] [105] . Because different E3s use different mechanisms to bind substrate, how they specify substrate lysine site (or sites) for ubiquitylation will vary. We discuss some examples below.
Lys125 prioritization on Sna3 by the HECT E3 Rsp5.
The HECT E3 Rsp5 mediates ubiquitylation, thereby regulating the sorting of most multivesicular body cargo proteins in yeast, including Sna3 . Rsp5 interacts directly with Sna3 to ubiquitylate its Lys125: the WW3 domain (a small 40 amino acid domain that binds defined proline-containing motifs) of Rsp5 binds to the PY motif in Sna3, which is separated from the target Lys125 by a 15-residue linker 82 . This linker is sufficient to bridge the gap between the catalytic cysteine of Rsp5 and the PY motif of Sna3 in the Rsp5~ubiquitin-Sna3 complex (FIG. 6a) . Shortening of this linker to less than ten residues strongly reduces ubiquitylation of Sna3, suggesting that the N-and C-lobes of Rsp5 cannot rotate to reach the target Lys125 during substrate ubiquitylation. The distance between the active site of Rsp5 and the PY motif of Sna3 seemingly selects the lysine ubiquitylation site 82 .
Site-specific monoubiquitylation of H2A by RNF2-BMI1. Monoubiquitylation of Lys119 in histone H2A by the heterodimeric RING E3 RNF2-BMI1 complex is important for Polycomb-group proteins to mediate gene silencing 110 . In the crystal structure of the RNF2-BMI1-UBE2D3 complex bound to the nucleosome core particle (NCP) 103 (FIG. 6b) , the RING domain is anchored onto the NCP through interactions with all four histones, whereas UBE2D3 interacts with both the nucleosomal DNA and the C terminus of H2A, thereby restricting RING mobility and the orientation of the E2 and specifying the substrate lysine for ubiquitylation. Usually, substrate lysine modification by RING E3s with the UBE2D family of E2s is promiscuous, but in this configuration, the accessibi lity of the catalytic cysteine from the E2 is limited to a specific substrate lysine. For RING E3s to build ubiquitin chains, resulting in polyubiquitylation, either the RING-E2 module or the ubiquitylated segment of substrate must rotate. In the RNF2-BMI1-UBE2D3-NCP complex, UBE2D3, nucleosomal DNA and histones H3 and H4 surround the C terminus of H2A, thereby restricting movement of the substrate. Because both the RING-E2 and substrate elements are constrained in the RNF2-BMI1-UBE2D3-NCP complex, only monoubiquitylation occurs.
Lysine selection with a mobile RING domain. In E3s such as CBL 61, 111, 112 , CRL 64, [113] [114] [115] and APC/C 104, 105, 116 , a flexible linker between the RING and other domains allows the E2~ubiquitin-bound RING domain to adopt multiple conformations. APC/C facilitates all known protein degradation events controlling mitotic exit. More than 50 substrates have been identified in genome-wide studies 117 ; however, this E3 shows remarkable lysine selectivity and tightly regulates its chain elongation. So how can the large conformational flexibility of APC/C be reconciled with its high selectivity of substrate lysine residues?
The ubiquitin ligase activity of the complex is stimulated by its interaction with a co-activator protein, CDH1, which induces a conformational change in the APC2 and APC11 subunits 116 . This conformational change enables the establishment of bipartite inter actions of APC/C with UBE2C, whereby the RING domain APC11 binds UBE2C via canonical E2-RING inter actions and the winged-helix B (WHB) domain of APC2 interacts with the backside of UBE2C (REF. 105) (FIG. 6c) . This bipartite UBE2C binding restricts the orientation of the APC11-APC2-UBE2C module such that the active site of UBE2C prioritizes lysine residues residing ten resid ues away from D-box and KEN-box substrate-binding motifs of CDH1 (REFS 104,105) .
Positioning of ubiquitin for chain elongation. To build a specific ubiquitin linkage during polyubiquitylation, a particular lysine from a ubiquitin initially ligated to a substrate (acceptor ubiquitin) must be poised for ligation with another ubiquitin (donor ubiquitin). Ubiquitin chain linkage specificity depends on the E2 pairing for RING E3s and the E3 itself for HECT and RBR E3s 4, 13, 88, 118 . Current structural understanding of acceptor ubiquitin positioning for generating specific ubiquitin-ubiquitin linkages is limited to two examples: RING E3-UBE2N-UBE2V2-catalysed Lys63-linked ubiquitin chains, in which UBE2V2 determines chain specificity 62, 119 , and HOIP-catalysed linear ubiquitin chain formation, in which the E3 determines chain specifi city 88 . Both UBE2V2 and HOIP harbour a ubiquitin-binding domain that binds acceptor ubiquitin and orients its Lys63 (in the case of UBE2V2) or its Met1 (in the case of HOIP) towards the catalytic cysteine for ligation. However, it remains unclear exactly how these E3s position ubiquitylated substrate for chain elongation.
Recent studies of APC/C have revealed a novel mechanism of polyubiquitylation whereby acceptor ubiquitin at the tip of a growing substrate ubiquitin chain is tracked, and E3 and E2 function together to determine chain specificity 120, 121 . As discussed above, APC/C uses a co-activator, CDH1 (or CDC20), to recognize and bind
Ub Ubiquitin
Thioester bond Lys Catalytic Cys In this way, lysine residues at least ten residues away from the PY WW3-binding motif in the substrate are prioritized for ubiquitylation. b | Structure of RNF2-BMI1-UBE2D3 complex bound to the nucleosome core particle (NCP) (PDB: 4R8P). Lys119 of HOIP, the target for monoubiquitylation in this reaction, is shown as a black sphere and the catalytic cysteine (Cys85) of UBE2D3 is shown as a yellow sphere. The interactions between the RNF2-BMI1-UBE2D3 complex and the NCP restrain UBE2D3 and H2A movement such that the catalytic cysteine of UBE2D3 can only be juxtaposed with the Lys119 of H2A, thereby catalysing a site-specific ubiquitylation. c | APC/C-catalysed substrate ubiquitylation and polyubiquitin chain formation. APC11 binds UBE2C~ubiquitin via the canonical RING, in a manner involving E3-E2~ubiquitin interactions as shown in FIG. 3 . In addition, the winged-helix B (WHB) domain of APC2 contacts the backside of UBE2C. These bipartite interactions fix the UBE2C~ubiquitin orientation such that the thioester bond is ~40 Å away from the D-box and KEN-box binding sites on the substrate receptor CDH1, thereby prioritizing substrate lysine residues located ten residues away from D-box and K-box motifs of the substrate for ubiquitylation. Once the substrate has been modified with a single ubiquitin, APC/C recruits UBE2S~ubiquitin (through the interaction between APC2 and C-terminal LRRL motif of UBE2S) and adds further molecules of ubiquitin, tracking the tip of the growing ubiquitin chain, leading to ubiquitin chain elongation. During this process, APC11 binds the acceptor ubiquitin (Ub Acc , functioning as a substrate; in green) using a surface distinct from its E2~ubiquitin-binding site and presents this acceptor ubiquitin to a UBE2S~ubiquitin complex (bound to donor ubiquitin Ub D ; coloured wheat) for ubiquitin chain elongation. The APC/C complex is shown as an outline.
substrates containing D-or KEN-box motifs and the APC11 RING to recruit UBE2C~ubiquitin. This initial recruitment of UBE2C~ubiquitin allows the transfer of ubiquitin directly to the substrate 122 (FIG. 6c) . Subsequently, APC/C recruits another E2~ubiquitin complex, namely UBE2S~ubiquitin (which this time is bound to APC2 through the C-terminal LRRL motif of UBE2S) 116, 123, 124 , thereby enabling UBE2S-mediated Lys11-linked ubiquitin chain elongation 120, 121 (FIG. 6c) . Finally, a distinct hydrophobic patch on the APC11 RING domain, opposite the UBE2C-binding surface, functions to bind the acceptor ubiquitin. These interactions massively enhance the catalytic efficiency of the APC/C-UBE2S complex and promote Lys11-linked polyubiquitylation, presumably by enabling juxtaposition of the active site of UBE2S with the acceptor ubiquitin lysine on the substrate.
These examples illustrate a common mechanism of ubiquitin chain elongation, whereby an E2-E3 or E3 cata lytic module is secured in a conformation that juxtaposes the ubiquitin thioester with select substrate lysine site (or sites) for ligation and chain elongation. For each example, structural features of the E3, E2 and substrate determine lysine selectivity and subsequent ubiquitin chain formation. Future studies of other E3-substrate systems will reveal how different structural features regulate ubiquitylation.
Regulation of E3 activity
Over the past 15 years, numerous mechanisms such as post-translational modifications of E2, E3 and substrates, as well as binding of protein partners and small molecules, exemplified how E3s are regulated throughout their catalytic cycle 21 . Recent studies have demonstrated that all three classes of E3s are also regulated by autoinhibitory mechanisms involving catalytically incompetent E3 conformations in which E2~ubiquitin cannot be recruited or the structural flexibility of the E3 is limited. It is apparent that domains other than those that define each class of E3 are involved in the autoinhibition; hence, how autoinhibition and activation are mediated will largely depend on the E3 and its domain composition. Here, we describe an example from each class of E3s of mechanisms governing the autoinhibition and activation of these proteins.
Autoinhibition and activation of cIAP1. cIAP1 (also known as BIRC2) is a dimeric RING E3 that has a central role in the NF-κB signalling cascade and programmed cell death 125 . cIAP1 contains three N-terminal baculoviral IAP repeat (BIR1-3) domains followed by a UBA domain, a caspase activation and recruitment domain (CARD) and a RING domain. In the crystal structure of cIAP1 lacking the BIR1 and BIR2 domains, cIAP1 is in an inactive conformation whereby the RING domain is sequestered between the BIR3, UBA and CARD domains and the protein is a monomer (FIG. 7a) . RING sequestration prevents dimerization, thereby impairing E2~ubiquitin recruitment 126, 127 . SAXS analyses showed that cIAP1 is dynamic and undergoes global conformational changes whereby the BIR3 peptide-binding groove is exposed 128 . Binding of second mitochondrial activator of caspases (SMAC) peptide or a SMAC peptide mimetic to the BIR3 domain disrupts this autoinhibited conformation, resulting in rearrangement of the BIR3, UBA and CARD domains, which enables RING domain dimerization and subsequent E2~ubiquitin recruitment, thereby inducing ubiquitin ligase activity 126, 129 (FIG. 7a) .
Autoinhibition and activation of SMURF2. The NEDD4 family of HECT E3s, including SMURF1, SMURF2, ITCH, NEDD4_1 and NEDD4_2, share a similar domain architecture containing an N-terminal C2 domain followed by two to four WW domains and a C-terminal HECT domain and are regulated by autoinhibition [130] [131] [132] [133] [134] [135] (FIG. 7b) . The mechanism of autoinhibition is the best characterized for SMURF2, for which autoinhibition is governed by interactions between the C2 and HECT domains 135 . NMR analyses have revealed that interactions between the C2 domain and the N-lobe of the HECT domain restrict the C-lobe to an inactive conformation in which transthiolation is unsupported 135, 136 ( FIG. 7b) . Moreover, this interaction partially buries the N-lobe non-covalent ubiquitin-binding surface essential for E3 processivity 136 . SMURF2 is activated upon binding of the adaptor protein SMAD7. Interactions between the PY motif of SMAD7 and the WW domain of SMURF2 as well as between the N-terminal domain of SMAD7 and the HECT domain of SMURF2 release the C2 domain 135, 137 (FIG. 7b) . Moreover, SMAD7 assists E2 binding by SMURF2 (REF. 80 ).
Autoinhibition and activation of PARKIN. In RBR E3s with characterized autoinhibitory mechanisms, various domains outside the RBR motif mediate autoinhibition [93] [94] [95] [96] [97] [98] [99] 138 . Of the three RBR E3s that have structural data available, PARKIN is the best-characterized example. PARKIN plays an important part in mitochondria quality control. When mitochondria are damaged, PINK1 kinase accumulates on the outer mitochondrial membrane and recruits PARKIN, which is initially inactive 139 . PINK1 then phosphorylates Ser65 in the ubiquitin-like (UBL) domain of PARKIN (this domain has a structural fold similar to ubiquitin and contacts the RING1 domain in the autoinhibited state). This process enhances the ubiqui tin ligase activity of PARKIN and enables the formation of polyubiquitin chains on the surface of mitochondrial membranes [140] [141] [142] . PINK1 also phosphorylates Ser65 on the ubiquitin molecules comprising the polyubiquitin chain 118, [143] [144] [145] . This ubiquitin phosphorylation further stimulates ubiquitylation by PARKIN, as binding of phospho-Ser65 ubiquitin increases the activity of unphosphoryl ated PARKIN and enhances PINK1-dependent phosphorylation of Ser65 on PARKIN 118, 146, 147 . This synergistic effect establishes a feed-forward mechanism 118 to ensure that PARKIN is activ ated and able to efficiently ubiquitylate mitochondrial outer membrane proteins 148, 149 to promote mitophagy. In the autoinhibited state of PARKIN, there is a large gap between the RING1 domain and the RING2 catalytic cysteine in which E3~ubiquitin formation is unsupported [94] [95] [96] [97] 138, 150 (FIG. 5c) . Moreover, the RING0 domain binds the RING2 domain and masks the catalytic Figure 7 | Mechanisms of autoinhibition and activation of E3s. a | cIAP1 domain composition and the mechanism of its autoinhibition and activation. cIAP1 domains comprise three baculovirus inhibitor of apoptosis protein repeat domains (BIR1-3), a ubiquitin-associated domain (UBA), a caspase activation and recruitment domain (CARD) and a RING domain. In solution, cIAP1 adopts a closed conformation in which the ubiquitin-conjugating enzyme (E2)~ubiquitin (~ indicates a thioester bond) binding and dimerization surfaces of the RING domain are occluded. A second mitochondrial activator of caspases (SMAC) mimetic compound binds the BIR3 domain and shifts cIAP1 to an extended conformation. This extension enables RING domain dimerization, which is critical for binding and priming E2~ubiquitin for catalysis. b | SMURF2 domain composition and the mechanism of its autoinhibition and activation. The C2 domain binds both the N-and C-lobes of the HECT (homologous to E6AP carboxyl terminus) domain, thereby preventing the rotation of the two lobes and blocking the binding of non-covalent ubiquitin (coloured lime), which is a factor important for processive polyubiquitylation. Addition of adaptor protein SMAD7 (or other stimuli) promotes the release of the C2 domain from the lobes, thereby facilitating E2-ubiquitin ligase (E3) transthiolation and non-covalent ubiquitin binding. c | PARKIN domain composition and the mechanism of its autoinhibition and activation. PARKIN adopts an autoinhibited conformation in which the E2~ubiquitin binding site on RING1 and the catalytic cysteine of RING2 are blocked by various intramolecular interactions. Moreover, the catalytic cysteine of RING2 in this conformation is distal from the modelled catalytic cysteine of E2 as shown in FIG. 5c . Phosphorylation of Ser65 (depicted as a red ball) of ubiquitin (thereby generating phospho-Ser65-ubiquitin (pUb), shown in yellow) and of the ubiquitin-like (UBL) domain of PARKIN by the kinase PINK synergistically activate PARKIN. The phosphorylated UBL domain is released from the RING1 domain, partially freeing the E2~ubiquitin binding surface. Phospho-Ser65-ubiquitin then binds a pocket created by RING0, RING1, extension helices (h E ) and IBR and induces straightening of h E . Notably, the RING1-h E -IBR-phospho-Ser65-ubiquitin complex of PARKIN adopts a conformation that resembles RING1-h E -IBR-ubiquitin Allo in the HOIPUBE2D2~ubiquitin structure ( (FIG. 5e,g ); ~ denotes a covalent interaction used for crystallization purposes), suggesting a similar mechanism in E2~ubiquitin recruitment of both enzymes, although this hypothesis remains to be investigated. d | Crystal structure of PARKIN bound to phospho-Ser65-ubiquitin (pUb) (PDB: 5CAW). Structural domains are coloured as in part c. REP, repressor element.
cysteine (FIGS 5a,7c) . Finally, an additional repressor element (REP) within the RBR motif and the N-terminal UBL domain occlude the E2~ubiquitin-binding site on the RING1 domain [94] [95] [96] [97] 150 . Phosphorylation of Ser65 on PARKIN releases the UBL domain from RING1 to allow E2~ubiquitin binding and alters the RING0-RING1 interface to promote phospho-Ser65 ubiquitin binding 97, 118, 146, 150, 151 . Phospho-Ser65 ubiquitin binding to the RING1-IBR surface opposite the E2~ubiquitin-binding site induces straightening of a 'bent' RING1-IBR helix and this induces conformational changes in the IBR-REP region, which also promote the release of the UBL domain from PARKIN 151 (FIG. 7c,d ). Activated PARKIN and HOIP have similar RING1-IBR conformations, suggesting that straightening of the RING1-IBR linker helix may be a prerequisite for E2~ubiquitin binding to RBR E3s 92 .
Conclusions and future perspectives Our understanding of the pivotal roles that E3s have in various cellular processes has grown exponentially. We now also better understand how E3s function on a molecular level. The capacity of E3s to mediate ubiquitin chain formation depends on the ability to recruit E2~ubiquitin and to promote ubiquitin transfer. Spatial arrangements of E3-E2-substrate complexes dictate substrate ubiquitylation patterns.
Technologies have only advanced enough in the past decade to support the preparation of sufficient quantities of E2~ubiquitin and E3~ubiquitin complexes suitable for structural and biochemical analyses. Consequently, we have gained several insights into the mechanisms underlying E3-mediated ubiquitylation and regulation of E3s. However, given that current structural studies encompass only a fraction of all E3s, future studies are required to uncover the functions and mechanisms of other uncharacterized E3s. Chemical crosslinkers such as those used in the studies of Rsp5 (REF. 82) and APC/C 105 will facilitate structural studies of intermediates in E3-catalysed reactions, allowing investigations into distinct catalytic steps in the mechanisms of E3-catalysed substrate ubiquitylation and polyubiquitylation. Furthermore, recent methods for introducing site-specific ubiquitin modifications to substrates [152] [153] [154] [155] [156] [157] [158] will be useful tools for generating mono ubiquitylated or polyubiquitylated substrates to further dissect E3-catalysed polyubiquitylation. Finally, there is a growing interest in targeting selected E3s for cancer therapy based on the role of E3s in regulating the stability of tumour suppressor proteins or oncogenes 159 . A better understanding of the mechanisms of E3-catalysed reactions and their regulation will greatly aid the development of such E3 inhibitors.
